GTHX G1 Therapeutics Inc.

21.46
-0.46  -2%
Previous Close 21.92
Open 21.78
Price To Book 2.58
Market Cap 805,234,846
Shares 37,522,593
Volume 371,206
Short Ratio
Av. Daily Volume 483,779
Stock charts supplied by TradingView

NewsSee all news

  1. G1 Therapeutics Presents First Clinical Data on Oral SERD G1T48 Demonstrating Safety and Tolerability in Patients with Advanced Breast Cancer at ESMO 2019

    -- Company to host investor and analyst event, webcast and conference call today at 12:45 p.m. ET -- RESEARCH TRIANGLE PARK, N.C. and BARCELONA, SPAIN, Sept. 29, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:

  2. G1 Therapeutics Presents Updated Data at ESMO 2019 from Randomized Phase 2 Trial of Trilaciclib in Combination with Chemotherapy in Metastatic Triple-Negative Breast Cancer Demonstrating Significant Improvement in Overall Survival

    -- Trial results published simultaneously in The Lancet Oncology -- -- Company also to present updated Phase 2 results demonstrating myelopreservation benefits in small cell lung cancer (SCLC) patients

  3. G1 Therapeutics to Present New Clinical Data Across Pipeline at European Society for Medical Oncology (ESMO) 2019 Congress

    -  Company to present first clinical data on oral SERD G1T48 in breast cancer - - Overall survival data on trilaciclib in women with metastatic triple-negative breast cancer (mTNBC) accepted for late-breaking oral

  4. G1 Therapeutics to Present at H.C. Wainwright Annual Global Investment Conference on September 9, 2019

    RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced that Chief Financial Officer Jennifer Moses will present a

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data at ESMO 2019 noted OS of 20.1 months, compared with 12.6 months for chemotherapy.
Trilaciclib
Triple-negative breast cancer
Phase 1/2 poster at ESMO September 28, 2019.
Tagrisso and Lerociclib (G1T38)
EGFR mutation-positive non-small cell lung cancer (NSCLC)
Phase 2 data presented at ESMO September 29, 2019.
Trilaciclib plus Tecentriq
First-line small-cell lung cancer
Phase 1b additional data due 4Q 2019.
Lerociclib (G1T38) plus Faslodex
ER+ breast cancer
NDA filing due 2020.
Trilaciclib
Second/third-line small-cell lung cancer
Phase 2 patient-reported outcomes (PRO) presented at MASCC meeting June 21, 2019.
Trilaciclib
Small-cell lung cancer
Phase 1/2 preliminary data ESMO 2019 noted 1/19 PRs. Clinical benefit rate 3/19. Phase 3 planned for 2020.
G1T48
ER+, HER2- breast cancer

Latest News

  1. G1 Therapeutics Presents First Clinical Data on Oral SERD G1T48 Demonstrating Safety and Tolerability in Patients with Advanced Breast Cancer at ESMO 2019

    -- Company to host investor and analyst event, webcast and conference call today at 12:45 p.m. ET -- RESEARCH TRIANGLE PARK, N.C. and BARCELONA, SPAIN, Sept. 29, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:

  2. G1 Therapeutics Presents Updated Data at ESMO 2019 from Randomized Phase 2 Trial of Trilaciclib in Combination with Chemotherapy in Metastatic Triple-Negative Breast Cancer Demonstrating Significant Improvement in Overall Survival

    -- Trial results published simultaneously in The Lancet Oncology -- -- Company also to present updated Phase 2 results demonstrating myelopreservation benefits in small cell lung cancer (SCLC) patients

  3. G1 Therapeutics to Present New Clinical Data Across Pipeline at European Society for Medical Oncology (ESMO) 2019 Congress

    -  Company to present first clinical data on oral SERD G1T48 in breast cancer - - Overall survival data on trilaciclib in women with metastatic triple-negative breast cancer (mTNBC) accepted for late-breaking oral

  4. G1 Therapeutics to Present at H.C. Wainwright Annual Global Investment Conference on September 9, 2019

    RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced that Chief Financial Officer Jennifer Moses will present a